skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.06d (Release date: 2017-06-26)
SearchBox Top
SearchBox Bottom
Atrasentan Hydrochloride (Code C1779)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Atrasentan Hydrochloride

Definition: The orally available hydrochloride salt of pyrrolidine-3-carboxylic acid with potential antineoplastic activity. As a selective antagonist of the endothelin-A (ETA) receptor, atrasentan binds selectively to the ETA receptor, which may result in inhibition of endothelin-induced angiogenesis and tumor cell proliferation.

Display Name: Atrasentan Hydrochloride

Label: Atrasentan Hydrochloride

NCI Thesaurus Code: C1779 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C0387926  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
(+)-A 127722
(2R,3R,4S)-4-(1,3-Benzodioxo-5-yl)-1-(2-(dibutylamino)-2-oxoethyl)-2-(4-methoxyphenyl)-3-pyrrolidinecarboxylic Acid Monohydrochloride
Atrasentan Hydrochloride

External Source Codes: 
CAS Registry Number 195733-43-8 (see NLM ChemIDplus info)
NSC Code 720763 (see NCI DTP info)
PDQ Closed Trial Search ID 38333
PDQ Open Trial Search ID 38333 (check for NCI PDQ open clinical trial info)
UMLS CUI C0387926

Other Properties:
     Name Value (qualifiers indented underneath)
Chemical_Formula C29H38N2O6.ClH
code C1779
Contributing_Source CTRP
Contributing_Source FDA
Legacy_Concept_Name Atrasentan
Semantic_Type Organic Chemical
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom